-Karen Gelmon Researcher Activity Profile

Research Author Detailed Information 

Karen Gelmon Publication Rate By Year

Karen Gelmon has published 7 paper(s) in 2007, 5 paper(s) in 2008, for a total of 12 research publications in total.

Karen K Gelmon Author Information

LAST NAME: gelmon

FIRST NAME: karen

INITIALS: K

AFFILIATION:

Papers

Karen Gelmon's Publication Record

1. Quantitative justification of the change from 10% to 30% for human epidermal growth factor receptor 2 scoring in the American Society of Clinical Oncology/College of American Pathologists guidelines: tumor heterogeneity in breast cancer and its implications for tissue microarray based assessment of outcome. Year Published: 2007
Department of Pathology, Yale University School of Medicine, New Haven, CT 06520-8023, USA.
2. Decreased levels of hypoxic cells in gefitinib treated ER(+) HER-2 overexpressing MCF-7 breast cancer tumors are associated with hyperactivation of the mTOR pathway: therapeutic implications for combination therapy with rapamycin. Year Published: 2007
Department of Advanced Therapeutics, British Columbia Cancer Agency, 675 West 10th Ave., Vancouver, BC, Canada, V5Z 1L3, vdragows@bccrc.ca.
3. Quantitative justification of the change from 10% to 30% for human epidermal growth factor receptor 2 scoring in the American Society of Clinical Oncology/College of American Pathologists guidelines: tumor heterogeneity in breast cancer and its implications for tissue microarray based assessment of outcome. Year Published: 2007
Department of Pathology, Yale University School of Medicine, New Haven, CT 06520-8023, USA.
4. Six-Month Follow-up of Patient-Rated Outcomes in a Randomized Controlled Trial of Exercise Training during Breast Cancer Chemotherapy. Year Published: 2007
Faculty of Physical Education and Recreation, University of Alberta, E-488 Van Vliet Center, Edmonton, Alberta, Canada T6G 2H9. kerry.courneya@ualberta.ca.
5. Chemotherapy for oestrogen-receptor-negative breast cancer. Year Published: 2008
British Columbia Cancer Agency, Vancouver, BC, Canada V5Z 4E6.
6. HER2 testing in a population-based study of patients with metastatic breast cancer treated with trastuzumab. Year Published: 2008
Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, 600 University Ave, Toronto, Ontario, Canada M5G 1X5. fomalley@mtsinai.on.ca
7. Decreased levels of hypoxic cells in gefitinib treated ER+ HER-2 overexpressing MCF-7 breast cancer tumors are associated with hyperactivation of the mTOR pathway: therapeutic implications for combination therapy with rapamycin. Year Published: 2007
Department of Advanced Therapeutics, British Columbia Cancer Agency, 675 West 10th Ave., Vancouver, BC, Canada, V5Z 1L3. vdragows@bccrc.ca
8. The development of a predictive model to estimate cardiotoxic risk for patients with metastatic breast cancer receiving anthracyclines. Year Published: 2008
, 283 Danforth Ave, Suite 448, Toronto, Canada, M4K 1N2, gdranit@ca.inter.net.
9. Chemotherapy for oestrogen-receptor-negative breast cancer. Year Published: 2008
British Columbia Cancer Agency, Vancouver, BC, Canada V5Z 4E6.
10. HER2 testing in a population-based study of patients with metastatic breast cancer treated with trastuzumab. Year Published: 2008
Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, 600 University Ave, Toronto, Ontario, Canada M5G 1X5. fomalley@mtsinai.on.ca
11. Decreased levels of hypoxic cells in gefitinib treated ER+ HER-2 overexpressing MCF-7 breast cancer tumors are associated with hyperactivation of the mTOR pathway: therapeutic implications for combination therapy with rapamycin. Year Published: 2007
Department of Advanced Therapeutics, British Columbia Cancer Agency, 675 West 10th Ave., Vancouver, BC, Canada, V5Z 1L3. vdragows@bccrc.ca
12. Six-month follow-up of patient-rated outcomes in a randomized controlled trial of exercise training during breast cancer chemotherapy. Year Published: 2007
University of Alberta, Edmonton, Alberta, Canada. kerry.courneya@ualberta.ca